Department of Urology, Beijing Friendship Hospital, Capital Medical University, 95 Yongan Road, Xicheng District, Beijing, China.
Beijing key laboratory of Tolerance Induction and Organ Protection in Transplantation, Beijing, 100050, China.
Diagn Pathol. 2021 Dec 14;16(1):118. doi: 10.1186/s13000-021-01181-5.
Transmission of malignancy is a notable problem that cannot always be absolutely predicted at the time of transplantation. In particular, donor-derived transmission of synovial sarcoma in solid-organ transplantation is a rare but catastrophic event.
We are the first to report three cases of synovial sarcoma transmitted from a single multi-organ donor in China. The donor died of respiratory failure caused by an intrathoracic tumor, which was diagnosed as benign at the time of donation. All three recipients developed synovial sarcoma 3-13 months after transplantation; all three cases were confirmed to be donor transmitted. The liver transplant recipient died of tumor metastasis after partial-allograft hepatectomy. The two renal-transplant recipients survived after comprehensive therapy, including allograft nephrectomy, withdrawal of immunosuppressants and targeted therapy with anlotinib.
This report highlights the importance of detailed donor assessment, close follow-up and timely treatment of unexpected donor-transmitted malignancy. Although pathology is the most important evidence for the exclusion of donors for malignant potential, it should be combined with tumor type, tumor size and speed of growth. Organs from donors with malignant potential should be discarded. Allograft nephrectomy should be considered after confirmation of renal-allograft synovial sarcoma. Anlotinib for synovial sarcoma seems to be effective and well tolerated during long-term follow-up.
恶性肿瘤的传播是一个显著的问题,在移植时并不能总是绝对预测到。特别是,实体器官移植中供体传播滑膜肉瘤是一种罕见但灾难性的事件。
我们首次报告了中国三例由单一多器官供体传播的滑膜肉瘤。供体因胸腔内肿瘤导致呼吸衰竭而死亡,供体捐献时被诊断为良性。所有三名受者在移植后 3-13 个月均发生滑膜肉瘤;所有三例均证实为供体传播。肝移植受者在部分肝移植后因肿瘤转移而死亡。两名肾移植受者在接受全面治疗后存活,包括肾移植切除、免疫抑制剂和安罗替尼靶向治疗的停药。
本报告强调了详细的供体评估、密切随访和及时治疗意外供体传播恶性肿瘤的重要性。虽然病理学是排除恶性潜能供体的最重要证据,但应结合肿瘤类型、肿瘤大小和生长速度。有恶性潜能的供体器官应予以丢弃。在确认肾移植滑膜肉瘤后,应考虑肾移植切除。安罗替尼治疗滑膜肉瘤在长期随访中似乎是有效且耐受良好的。